(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...

Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. August 7, 2025 ...

UroToday's exclusive Video Lecture content covering mCRPC Treatment.

ASCO 2025 BULLSEYE trial, Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy, androgen deprivation therapy (ADT), 177Lu-PSMA-617, PSMAddition.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Poster Session: Genitourinary Cancer - Prostate, Testicular, and Penile Cancer.

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured an alpha and other radionuclides session and a presentation by Dr. Alfred Morgenstern discussing 212 Pb-PSMA versus 225 Ac-PSMA. Dr.

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

High circulating IL-6/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in advanced renal cell carcinoma patients treated with PD-1 blockade. August 8, 2025 MtDNA copy number ...